Key Takeaways:
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is facing a securities class-action lawsuit after its stock price plummeted 71% following the rejection of its dry eye drug candidate by U.S. regulators.
"The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that the results of the reproxalap clinical trials were inconsistent," according to a statement from the law firm Bronstein, Gewirtz & Grossman, LLC, one of several firms that have filed suits.
The lawsuit, seeking to recover damages for investors, covers the class period between November 3, 2023, and March 16, 2026. On March 17, 2026, Aldeyra's stock fell by $2.99, or 70.7%, to close at $1.24 per share after the company announced it had received a Complete Response Letter from the U.S. Food and Drug Administration. The FDA stated that the clinical trials for reproxalap failed to provide "adequate, well-controlled" support for the drug's effectiveness, noting inconsistent results across different trials.
The rejection and subsequent lawsuits deal a significant blow to Aldeyra, as reproxalap was a cornerstone of its late-stage pipeline. Investors who suffered losses have until May 29, 2026, to file a motion to serve as lead plaintiff in the case. The legal proceedings will place Aldeyra's scientific validation and corporate disclosure practices under intense scrutiny, with the outcome being critical for the biotechnology company's future.
This article is for informational purposes only and does not constitute investment advice.
